SDZ 281-240
a newly developed macrolide of the ascomycin type that interferes with early T-cell activation; structure given in first source
Also Known As:
SDZ-281-240
Networked: 2
relevant articles (2 outcomes,
1 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
Related Diseases
| 1. | Psoriasis (Pustulosis Palmaris et Plantaris)
04/01/1996
- " To evaluate whether SDZ 281-240 exhibits antipsoriatic activity when applied topically, we tested 15 patients with severe, recalcitrant psoriasis, using a microplaque assay in randomized, double-blind, placebo-controlled study, comparing the therapeutic efficacy of the macrolide with a potent halogenated corticosteroid and vehicle. " 11/01/2002
- " Some psoriasis forms can be successfully treated with topical medicaments; serious and extensive forms cannot be cured without systemic treatment with retinoids (etretinate, acitretin, tazarotene) or with immunosuppressives (methotrexate, cyclosporine A, tacrolimus, SDZ 281-240). "
|
|
Related Drugs and Biologics